The devil is in the details. When you look at the gains in some small-cap names (including several biotech stocks) since the US election, it seems that investors are expecting more than a token reduction in the US corporate-tax rate.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.